Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat vs Enoxaparin in High Risk Bleeding Hemodialysis
NCT05874674Recruiting
- Sponsor
- Wonju Severance Christian Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Nafabelltan in thrombosis (2 arms), sponsored by Wonju Severance Christian Hospital. Primary endpoint: Number of patients with severe bleeding at 6 months. Started Dec 2023; status: recruiting.
02
Drugs
Nafabelltan
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT05874674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874674.